



Warfarin was approved as an anticoagulant in 1954 and 
has maintained the lead as the most commonly prescribed 
anticoagulant for many decades.[1] Countless number of 
patients have benefited from the life-saving benefits of 
warfarin. Perhaps, warfarin’s most famous patient was 
President Dwight Eisenhower who had myocardial infarction 
in 1955.[1]
Since the approval of warfarin, no other oral anticoagulant 
existed for patients who needed long-term anticoagulation 
therapy until the recent introduction of non-V itamin K 
antagonist oral anticoagulants (NOACs). The term non-VKA 
oral anticoagulants is now generally accepted following previous 
labeling as novel oral anticoagulants (NOACs),   direct acting 
anticoagulants (DOACs), target‑specific oral anticoagulant, 
oral direct inhibitor, and specific oral direct anticoagulant.[2]
One of the problems with the era of widespread clinical 
application of warfarin was the laboratory method used for 
dosage control, the prothrombin time (PT). This arose because 
the result (s) for a PT performed on a normal individual will 
vary according to the type of analytical system employed. This 
is due to the variations between different types and batches 
of manufacturer’s tissue factor used in the reagent to perform 
the test.[3]
This was solved with the reporting of results in International 
normalized ratio (INR). This provided a scientific method of 
monitoring the effect of warfarin and steered the patient away 
from under- and overcoagulation.[3] However, there were so 
many variables that effected the pharmacodynamics and 
pharmacokinetics of warfarin. This ranged from drug–drug 
interaction, food–drug interaction, and even disease–drug 
interaction.[4] This made monitoring of anticoagulant effect 
of warfarin cumbersome.
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Warfarin interacts with more than 250 drugs.[5,6] This meant 
that prescription and use of many drugs for patients on warfarin 
needed caution and vigilance to be able to keep the patient 
within therapeutic range and still stir the patient away from 
excessive bleeding and thrombosis.
Patients on warfarin anticoagulation also needed to watch 
food intake. Vitamin K-rich foods, Vitamin K-containing 
supplements, and green leafy vegetables will reduce the INR.[5] 
Many drugs with an antiplatelet effect like aspirin and other 
nonaspirin nonsteroidal anti‑inflammatory drugs will increase 
bleeding tendency.[7]
Liver disease can lead to increased bleeding through liver’s 
inability to synthesize clotting factors, the presence of 
concomitant thrombocytopenia due to portal hypertension, and 
through the presence of esophageal varices.[7] Hypothyroidism 
decreases the catabolism of the Vitamin K clotting factors 
and therefore decreases INR.[8] Hyperthyroidism will do 
the reverse.[4] Congestive heart failure can cause hepatic 
congestion of blood flow and inhibit warfarin metabolism, 
increasing INR particularly with frequent exacerbations or 
advanced heart failure.[7]
Patients with severe renal impairment or chronic kidney 
disease (CKD) will require a significantly reduced dose of 
warfarin to achieve therapeutic INR in comparison with 
those with normal kidney function. Patients with a CrCl of 
30–59 mL/min/1.73 m2 will need a 10% lower maintenance 
dose, while those with levels of <30 mL/min/1.73 m2 a 20% 
lower dose. This may be related to the downregulation of 
cytochrome P450 in CKD.[9]
Care of patients on long-term anticoagulation needed drugs 
that had markedly reduced drug interaction, less food and 
disease interaction, and could provide the convenience and 
noninvasiveness of oral drugs. NOACs came to fill in some 
of the gaps presented by warfarin. The advantages and 
disadvantages of NOAC when compared with warfarin are 
outlined in Boxes 1 and 2.
In 2010, the U. S. Food and Drug Administration (FDA) gave 
approval for the first NOAC, an oral direct thrombin inhibitor 
dabigatran (Pradaxa).[10] This was followed in 2011 with approval 
of the oral direct factor Xa inhibitor rivaroxaban (Xarelto) and 
again in 2012 with the FDA approval of the oral factor Xa 
inhibitor apixaban (Eliquis).[10]
NOACs are relatively new in Africa and how it will fit into 
the management architecture of anticoagulation services in 
Sub-Saharan Africa (SSA) that is weak, and in some cases, 
nonexistent is not known. We sort to examine the anticoagulation 
management services in Sub-Saharan Africa and see how it will 
cope with the introduction and use of NOACs.
Methods
We searched PubMed, Google Scholar, Medline, and African 
Journals OnLine for articles on anticoagulation management 
and non-VKA s oral anticoagulants. The search was from 
January 1990 to January 2020, a 30-year period. Search 
words included “anticoagulation clinics,” “anticoagulation 
management services,” “Dedicated anticoagulant clinics,” 
“Non vitamin K antagonist oral anticoagulants” (NOACs), 
and “Vitamin k antagonist oral anticoagulants,” all with 
the word “Africa.” We also searched the website of main 
Teaching and Specialist Hospitals seeking to find out those 
centers with active anticoagulation services. We defined 
anticoagulation clinics as services provided by specialists 
including cardiologists, hematologists, trained nurses, and 
clinical pharmacists dedicated toward achieving effective 
and safe anticoagulation. Centers where anticoagulants were 
prescribed without any definite program to organize the 
services for improved patient safety and effective care were 
excluded.
results
Anticoagulation is prescribed in many hospitals in SSA, but 
dedicated anticoagulant clinics or anticoagulation management 
services were found in very few countries.
Nigeria topped the list with up to six tertiary centers having 
anticoagulation clinics with consultant cardiologists and or 
hematologists in charge. South Africa had four anticoagulation 
clinics. Uganda had 3 centers providing anticoagulation 
services. Anticoagulation management services were also in 
place in one center each in Ghana, Kenya, Cameroun, Namibia, 
Ivory Coast, Ethiopia, and Botswana (see Table 1). Most other 
countries prescribed anticoagulation in the setting of routine 
medical care.
The anticoagulation clinics were mainly involved in the 
management and monitoring of warfarin in the different clinical 
conditions it is indicated. NOACs were not inculcated in the 
Box 1: Advantages of NOACs over warfarin
Quick onset of action obviates need for heparin/low-molecular-weight 
heparin bridging
Quick offset of action simplifies periprocedural management and reduces 
need for reversal agents
Decreased risk of intracranial bleeding translates to safer anticoagulant 
therapy
There are fewer drug and food interactions and so predictable 
anticoagulant effect
Box 2: Disadvantages of NOACs over warfarin
Reversal agents for oral factor Xa inhibitors not yet licensed and so 
physicians are concerned about uncontrollable bleeding. Management of 
patients who require urgent intervention may be complicated
There is limited access to standardized assays for drug level measurement 
and this complicates identification of bleeding patients who require 
reversal and timing of urgent surgery or intervention
The use of NOACs in patients with severe renal failure is contraindicated
Fecal excretion of active anticoagulant may predispose at-risk patients to 
gastrointestinal bleeding
Higher cost of NOACs will limits use in some countries and patient 
groups
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dedicated anticoagulation management services. NOACs 
were prescribed by specialist who were mainly cardiologists 
and hematologists who had adequate knowledge of their use. 
In some centers, the consultant worked with pharmacists and 
nurses to provide daily anticoagulation management services; 
otherwise, only once or thrice weekly service was delivered. 
Pharmacist-run anticoagulation clinic was found in Kenya. 
Nurse-run anticoagulation clinic was also found in South 
Africa. Most of the anticoagulation management services were 
provided in tertiary hospital setting. It is only in South Africa 
that anticoagulation services were provided in primary and 
secondary health center setting.
dIscussIon
The use of NOACs is guided by their pharmacokinetic and 
pharmacodynamic characteristics. The relationship between 
dose, drug concentration, and effect defines the therapeutics 
of any medicine. This knowledge is useful in the therapeutics 
of NOACs.
Therapeutics of anticoagulants
The NOACs have a rapid onset of action with peak 
concentrations achieved in 1–4 h. The half-life varies  from 
5 to 9 h for rivaroxaban, 12 h for apixaban, 9–14 h for 
edoxaban and 12–17 h for dabigatran.[11-14] Rivaroxaban and 
apixaban are metabolized via the cytochrome P450 system, 
particularly cytochrome P450 isoenzyme 3A4 (CYP3A4), 
whereas edoxaban and dabigatran undergo little cytochrome 
P450-mediated metabolism. All of the NOACs are substrates 
for P-glycoprotein (P-gp). The NOACs are excreted through 
the kidneys with dabigatran having up to 80% and apixaban 
the lowest, 25% excretion.
NOACs are indicated for the prevention of recurrent deep 
venous thrombosis (DVT) and pulmonary embolism (PE) in 
adults, treatment of DVT and PE and stroke prevention for 
patients with atrial fibrillation (AF). ARISTOTLE, ENGAGE 
AF-TIMI 48, RE-LY, and ROCKET AF trials demonstrated 
that NOACs had at least noninferior reductions in stroke and 
systemic embolism compared with warfarin.[15] Apixaban, 
dabigatran, edoxaban, and rivaroxaban are indicated by the 
European Medicines Agency and FDA for patients with 
nonvalvular AF defined as AF in the absence of rheumatic 
MS, a mechanical or bioprosthetic heart valve, or mitral valve 
repair.[16] In addition, the NOACs were associated with similar 
or lower rates of major or clinically relevant nonmajor bleeding 
and significantly decreased rates of intracranial bleeding 
compared with warfarin.[17-20]
NOACs are contraindicated in patients who have mechanical or 
bioprosthetic heart valve; the findings of the RE‑ALIGN study 
showed that dabigatran was less effective than warfarin for 
stroke prevention in patients with mechanical heart valves.[21] 
The explanation may be because medical devices, such as 
heart valves, trigger clotting by activating factor XII and may 
locally generate factor Xa and thrombin in concentrations that 
exceed those of the NOACs.
In contrast, by lowering the functional levels of the Vitamin 
K-dependent clotting factors, warfarin attenuates thrombin 
generation regardless of the trigger.There are also studies 
that show that warfarin attenuates thrombin generation 
induced by mechanical valves at INR values of ≥1.5, whereas 
dabigatran concentrations in excess of 260 ng/mL are required 
for equivalent suppression of thrombin generation.[21] These 
dabigatran concentrations are 5-fold higher than the targeted 
trough level of 50 ng/mL used in the RE-ALIGN study.[21] It 
is not known whether if by attenuating thrombin generation, 
rivaroxaban, apixaban, or edoxaban would be better than 
dabigatran for prevention of clotting on mechanical valves.
The main adverse effects of NOACs include bleeding, 
but there are also non hemorrhagic side effects such as 
hypersensitivity reactions, leukocytoclastic vasculitis, and 
hair loss. A study that investigated the associations between 
direct oral anticoagulants (DOACs) and risks of bleeding, 
ischemic stroke, venous thromboembolism, and all-cause 
mortality compared with warfarin showed Figure 1 is the 
Prisma diagram depicting the selection process that apixaban 
was found to be the safest drug, with reduced risks of major, 
intracranial, and gastrointestinal bleeding compared with 
warfarin. Rivaroxaban and low-dose apixaban were, however, 
associated with increased risks of all-cause mortality compared 
with warfarin.[22]
NOACs are associated with fewer drug–drug interactions and 
drug–disease interactions than VKAs, but there is need to keep 
an eye on the pharmacokinetics of medications coadministered 
and all comorbidities when NOACs are prescribed. As 
mentioned previously, rivaroxaban and apixaban are 
metabolized via the cytochrome P450 system, particularly 
CYP3A4, whereas edoxaban and dabigatran undergo little 
cytochrome P450-mediated metabolism. Therefore, the 
concentrations of rivaroxaban and apixaban can be increased 
or decreased by potent inhibitors or inducers of CYP3A4, 
respectively.[23,24] All of the NOACs are substrates for P-gp and 
potent inhibitors or inducers of P-gp can increase or decrease 
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80 titles/abstracts on 
anticoagulation, atrial fibrillation,
valvular heart disease, 
cardiomyopathy, venous 
thrombosis in Africa retrieved
50 articles/abstracts on 
anticoagulation in sub Saharan
 Africa considered
12 articles on dedicated anticoagulation 
clinics/haematology clinics in sub Saharan
Africa included in the review
Figure 1: The selection process
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the plasma concentrations of the NOACs, respectively. Table 2 
outlines important drug–drug interaction.
There are no foods to avoid when taking NOACs because these 
drugs do not interact with any food. This is unlike warfarin 
where green leafy vegetables affect its action.[25] Large amounts 
of alcohol may cause or trigger AF and can also increase the 
risk of bleeding. Therefore, it is recommended take not more 
than one drink daily.[25]
Since dabigatran and to a lesser extent, rivaroxaban and 
apixaban are excreted by the kidneys, drug accumulation can 
translate into accentuated anticoagulant effects.[26,27] Severe 
renal impairment and end-stage renal disease preclude use 
of these new oral anticoagulants and therapy with warfarin is 
recommended in patients with such conditions. NOACs are 
contraindicated in patients with hepatic disease associated with 
coagulopathy and clinically relevant bleeding risk including 
Child-Turcotte-Pugh C cirrhosis.[28,29] Rivaroxaban should also 
not be used in AF patients with Child B liver cirrhosis.
The use of NOAC in African countries will lack behind that of 
developed countries for some time. The first reason is the high 
cost of NOACs compared with warfarin. When cost is the only 
considered factor, warfarin rates much higher than NOAC as 
the preferred anticoagulant in most settings in Africa. However, 
other factors weigh even higher when the use of anticoagulants 
are considered. Benefits and risk factors are also important. 
Benefits of the anticoagulant therapy includes reductions in 
stroke and all-cause mortality, while risks include intracranial 
hemorrhage, gastrointestinal hemorrhage, minor bleeding and 
myocardial infarction.[30]
A structured benefit-risk assessment by IMI-PROTECT 
(Pharmacoepidemiological Research on Outcomes of 
Therapeutics by European Consortium) analyzed the benefit–
risk and cost assessment of oral anticoagulants used in the 
management of AF and came to the conclusion that apixaban 
should be considered as the preferred anticoagulant option, 
due to a better benefit–risk balance and a minor cost influence, 
followed by dabigatran, warfarin, and rivaroxaban. The 
task before the physician is to convince the patient-needing 
anticoagulation in African setting where payment is 
out-of-pocket because of the poorly developed health insurance 
system that warfarin is not the preferred anticoagulant in spite 
of the very low cost.
The second reason why the use of NOACs may not be the 
first choice of anticoagulant for some time is the considerable 
knowledge gap and poor anticoagulation management 
infrastructure in Africa. We had reported a multicenter study 
in Nigeria which involved 528 clinicians working in tertiary 
hospitals.[31] The aim was to evaluate clinicians practice 
patterns in anticoagulation therapy and prophylaxis in Nigeria. 
We discovered that only 52 (9.8%) respondents claimed that 
their institutions had an anticoagulation policy. The most 
prescribed anticoagulation agent was low-molecular-weight 
heparin (adjusted odds ratio [AOR]: 163, 95% confidence 
interval [CI]: 0.85–0.3.14, P = 0.19) and warfarin (AOR: 0.5, 
95% CI: 0.28–0.88 P = 0.02), while the fondaparinux was 
least prescribed (AOR: 1.74, 95% CI: 0.61–5.0 P = 0.44). 
NOACs where infrequently prescribed. Only 193 (36.6%) of 
the respondents routinely prescribed anticoagulation therapy 
when indicated.
Table 1: Chart of published articles describing dedicated anticoagulation clinics in sub‑Saharan Africa
Countries Published article
Nigeria 1. Anakwue RC, Nwagha T, Ukpabi O, et al. A survey of clinicians practice patterns in anticoagulation therapy & prophylaxis in South 
East Nigeria. Haematol Int J 2018;2:3
2. Anakwue R, Nwagha T, Ukpabi OJ, et al. Clinicians-related determinants of anticoagulation therapy and prophylaxis in Nigeria. Ann 
Afr Med 2017;16:164-9
3. Available from: file:///C:/Users/Dr%20Ralph%20A/Documents/Anticoagulation%20%20Nigeria%201c%20%20Specialist%20
hospitals.pdf
South Africa 1. Ebrahim AI, Bryer A, Cohen K, et al. Poor anticoagulation control in patients taking warfarin at a tertiary and district-level 
prothrombin clinic in Cape Town, South. South Afr Med J 2018;108:490-4.
2. Semakula JR, Mouton JP, Jorgensen A, et al. A cross-sectional evaluation of ve warfarin anticoagulation services in Uganda and South 
Africa
Cameroun Etoundi PO, Esiéne A, Bengono RB, et al. La maladie thromboembolique veineuse. Aspects épidémiologiques et facteurs de risque dans 
un hôpital Camerounais 2015; Health sciences and disease: 16:4
Ghana Olayemi E. Time in Therapeutic Range (TTR) of Ghanaian VTE Patients on Warfarin. ISTH Acad 2019;264830
Kenya Nyamu DG, Guantai AN, Osanjo GO, et al. Trends of anticoagulation control among adult outpatients on long-term Warfarin therapy in a 
Tertiary Teaching and Referral Hospital in Kenya. East Afr Med J 2018;95:7
Namibia Jonkman LJ, Marvelous P, et al. Assessment of anticoagulation management in outpatients attending a warfarin clinic in Windhoek, 
Namibia. Drugs Ther Perspect 2019;35:341-6
Ivory coast Coulibaly I, Anzouan-Kacou JB, Konin KC, et al. Atrial fibrillation: epidemiological data from the Cardiology Institute in Abidjan, Cote 
d’Ivoire. Med Trop 2010;70:371-4
Ethiopia Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis 
Ababa, Ethiopia: A retrospective cross-sectional study. BMC Health Serv Res 2017;6:389
Botswana Mwita JC, Francis JM, Oyekunle AA, et al. Quality of anticoagulation with warfarin at a tertiary hospital in Botswana. Clin Appl Thromb 
Hemost 2018;24:596-601
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The third reason is the fear of bleeding, particularly given 
the background of the lack of specific antidote to NOACs. 
However, the outcome of patients with major bleeds is no worse 
with the NOACs than with warfarin. Many trials including 
Randomized Evaluation of Long-Term Anticoagulant Therapy 
with Dabigatran Etexilate (RE‑LY) trial, Efficacy and Safety 
Study of Rivaroxaban with Warfarin for the Prevention of Stroke 
and Noncentral Nervous System Systemic Embolism in Patients 
with Nonvalvular AF (ROCKET-AF) trial sand Apixaban for 
the Prevention of Stroke in Subjects with AF (ARISTOTLE) 
trial have demonstrated that there is no evidence to support the 
belief that the lack of specific antidotes renders bleeding events 
with the NOACs more dangerous than those with warfarin. [10]
Other reasons include the fact that the use of NOAC has not 
been well validated in African subjects.[32] Indeed a significant 
limitation of all the NOAC trials with regard to the use of 
these drugs in the African population is that none of the trials 
included a large number of patients from Africa, and the 
percentage of black subjects overall was small.[32] Africans 
also have a disproportionably higher number of subjects with 
valvular (rheumatic) AF in whom NOAC is not indicated.
We do not have data needed for dosing of the NOACs in 
patients at extremes of body weight. The doses of apixaban 
and edoxaban are reduced in patients with low body weight, 
those of dabigatran and rivaroxaban are not.[10] Whether dose 
adjustment is needed for patients with body weight >150 kg 
is unknown because few such patients were included in the 
clinical trials.
The NOACs have been marketed as not needing monitoring. 
However, the RELY trial showed a correlation between 
dabigatran levels and bleeding and stroke outcomes in 
patients.[33] Hence, monitoring may be required to optimize 
the dosing of NOACs. However, tests to measure drug levels 
are not widely available, the within patient variability in 
drug levels is sufficiently wide that single measurements 
may provide misleading information, and the correlation 
between drug levels and clinical outcomes is confounded by 
important clinical characteristics, such as age, renal function, 
and concomitant medications.[33]
Information on the use of NOAC in Africa is not easily 
available because it is relatively new in Africa even though 
dabigatran, the first NOAC has been in use since 2010. 
Table 2: Non‑Vitamin K antagonist oral anticoagulants drug‑drug interactions
Class Drugs Dabigatran Rivaroxaban Apixaban Edoxaban
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Caution. If on verapamil 
give 110 mg twice daily
Avoid use particularly in 
renal impairment
Caution Caution
Protease inhibitors (Pgp 
inhibitors and CYP3A4 
inhibitors)













rifampicin, St John’s 
Wort
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avoided










when switching therapy 
or when UFH is given 
at doses necessary to 
maintain an open central 
venous or arterial catheter
Combination 
contraindicated except 
when switching therapy 
or when UFH is given 
at doses necessary 
to maintain an open 
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is given at doses 
necessary to maintain 
an open central 






or when UFH is 
given at doses 
necessary to 
maintain an open 
central venous or 
arterial catheter
Others Aspirin, clopidogrel 
NSAID’s
Combination not 

























LMWH: Low‑molecular‑weight heparin, UFH: Unfractionated heparin, NSAID’s: Nonsteroidal anti‑inflammatory drugs
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Approvals for NOAC in Africa started in 2011 and dabigatran 
and rivaroxaban are now widely in use in Namibia,[34] Kenya[35] 
South Africa,[36] Nigeria.[37] Uganda[38] and other countries.[32]
The use of warfarin has declined from 87.5% to 72% 
through 2008–2014,[39] compared to that of NOAC that has 
increased to 15.5% globally. In 2016, there are 4,210,000 
prescriptions for NOAC in the USA alone. Indeed, NOAC 
prescriptions exceeded those for warfarin in outpatient office 
visits for AF, with rivaroxaban being the most frequently 
prescribed DOAC (47.9%), followed by apixaban (26.5%) 
and dabigatran (25.5%).[40,41]
Anticoagulation management
In the USA, more than half of the anticoagulation clinics have 
adjusted their practice to cater for the needs of patients on 
NOACs as well as those taking warfarin.[40,41] About 10% of 
the volume of service by these clinics are due to patients on 
NOACs.[41] This proportion will increase as more patients are 
placed on NOACs.
Before the advent of NOACs, anticoagulation management 
service had existed for patients on warfarin and other 
anticoagulants. Anticoagulation management service is 
fairly well developed in USA and Europe and nonphysicians 
including clinical pharmacists and clinical nurses are now part 
of the staff mix. There are well established anticoagulation 
clinics run by clinical pharmacists and clinical or registered 
nurses who prescribe, order laboratory tests and adjust 
anticoagulation doses.[42] Clinical pharmacists are licensed 
practitioners with advanced education and training who 
practice in all types of patient care settings with a focus on 
comprehensive medication management.[42] In other words, 
clinical pharmacists perform functions beyond fundamental 
dispensing and order-processing activities that are often 
associated with staff pharmacists.
In developed countries, clinical pharmacists have 
good knowledge of pharmaceutical products including 
pharmacokinetics and pharmacodynamics of drug action, 
drug interactions, and adverse effects and therefore are 
professionally qualified to manage anticoagulant prescriptions 
within defined treatment protocols.[43] There are many warfarin 
clinical–pharmacist-run anticoagulation clinics which have 
achieved outcomes at a level consistently exceeding INR 
readings in therapeutic target range and time in therapeutic 
range.[44,45] Indeed, clinical pharmacists could significantly 
increase patient access to professional advice and testing, 
leading to improved INR control and self-care.[46,47] In 
Africa, there is a paucity of clinical pharmacists trained in 
anticoagulation management service.
Clinical or specialist nurse-run anticoagulation clinics are also 
common in developed countries. They are knowledgeable in the 
science and practice of anticoagulation and can provide services 
that can enable the patient benefit from the lifesaving effect of 
anticoagulants by improving the time within therapeutic range 
whilst reducing the risk of complications. They are capable 
of educating the patient and creating the relationship that will 
help improve compliance to anticoagulants.[48]
Table 3: The different areas of emphasis between Vitamin K antagonist clinic and non‑Vitamin K antagonist 
anticoagulation clinic
Parameters VKAs clinic Non‑Vitamin K antagonists anticoagulantion clinic
Baseline tests Hb, liver function test, kidney 
function test. Repeat as and when 
necessary
Hb, liver function test, kidney function test. Repeat yearly or more frequent in 
patients with renal impairment, change in drug or clinical state or age >75 years. 
NOACs are contraindicated for patients with Child-Pugh category C hepatic 
insufficiency and CrCl of 15‑30 mL/min
Monitoring tests INR is needed to ensure time 
within therapeutic range
Activated partial thromboplastin time or dilute thrombin time for dabigatran, aPTT 
>2.5 times control may indicate overanticoagulation
Prothrombin or anti-Factor Xa assays for direct Factor Xa inhibitors are done not 
as a regular monitoring tests but in emergency conditions
Determination of clinical 
end point
Absence of thrombotic events and 
time within therapeutic range
Absence of thrombotic events
Drug-drug interactions Very important Important
Drug-food interactions Very important Less important
Revisits Monthly initially and then longer 




determinant of safe and 
effective anticoagulation
INR Adherence to medication
Half-life of drug and 
implication
Long half-life and skipping of 
drug for 1-2 days may not have 
significant implication
Short half‑life, so skipping of drug for 1‑2 days will affect benefit of 
anticoagulation
Education Targeted on drug-drug interaction, 
drug-food interaction
Targeted on adherence with shorter half-lives than warfarin, adherence to the 
NOACs is essential. Care giver education is very important
Hb: Hemoglobin, NOACs: Non-Vitamin K antagonist oral anticoagulants, INR: International normalized ratio, CrCl: Creatinine clearance, aPTT: Activated 
partial thromboplastin time, TTR: Time in therapeutic range, VKAs: Vitamin K antagonist anticoagulants
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In Africa, there are probably few clinical pharmacists and 
nurses in the same mode as obtains in USA. A pilot study to 
find the effect of clinical pharmacist intervention in Ahmed 
Gasim cardiac surgery and renal transplant center warfarin 
clinic in Sudan showed a significant (P < 0.01) improvement 
in INR control and a significant (P < 0.05) reduction in 
incidence of bleeding after clinical pharmacist intervention.[49] 
Hospitalization due to warfarin related complications (bleeding, 
high INR, low INR) was also significantly (P < 0.001) reduced. 
Hence, clinical pharmacists’ intervention in warfarin therapy 
even in Africa can improve INR control and reduce bleeding 
and hospitalization due to warfarin complications. This shows 
that the type of outcome seen in developed countries can be 
obtained in Africa if clinical pharmacists are available.
Anticoagulation structure is poorly developed in Africa. 
There are no anticoagulation services in primary and 
secondary hospitals and there is only limited number in 
most tertiary hospitals. In most hospitals in Africa, patients 
get anticoagulation prescription with little or no monitoring. 
The few anticoagulation management services are domiciled 
in tertiary hospitals where physicians work. This type of 
structure has made anticoagulation available to only the few 
lucky patients leaving the majority with a tremendous burden 
of thrombotic diseases.
However, with a proper anticoagulation policy, physicians 
working together with the right staff‑mixture can deliver 
accepted anticoagulation service. Multiprofessional 
anticoagulation management service brings physicians, 
pharmacists, nurses, and dieticians in one clinic to deliver 
service. This type of service is ideal in tertiary hospitals 
where physicians can diagnose thrombotic diseases, prescribe 
anticoagulants, and the pharmacists and nurses take over the 
follow‑up and refilling of anticoagulants. All complications 
arising from anticoagulation are managed by the physicians. 
This type of multiprofessional collaboration has been shown 
to improve efficacy of anticoagulants and reduce costs in 
Africa, Asia, Europe, and USA.[50-52] Cardiologists and 
hematologists have often been the physicians who drive this 
type of institutionalized anticoagulation management service.
Anticoagulation management in the era of NOAC
It had seemed that with the advent of NOACs the anticoagulation 
management service will be dismantled. This thinking is borne 
out of the belief that NOAC is given orally, does not require 
monitoring, has limited drug interaction, and has reduced 
adverse effects. There are some changes that should accompany 
management of NOACs so as to fit into already existing VKA 
clinics. The differences between VKA clinics and  NOACs 
clinics are depicted in Table 3. The clinics are meant to run 
concurrently and so suitable adjustments are required.
The service for patients on NOACs will require proper 
documentation just as in warfarin therapy though with some 
adjustment in protocol. Drug–drug and drug–food interactions 
may be greatly limited with NOAC in comparison with 
warfarin but there are reasons to tread cautiously. Patients 
who are on NOAC and need surgery or a medical procedure[53] 
or have renal impairment will need adjustment of therapy.[23]
In the new era of NOAC, it is important to strengthen 
anticoagulation management service infrastructure in African 
countries. There has to be an anticoagulation policy that 
should birth anticoagulation services. Anticoagulation services 
incorporating NOACs should aim to (1) to assist patients 
and clinicians with selecting the most appropriate drug and 
dose from a growing list of anticoagulant options (including 
warfarin), (2) to help patients minimize the risk of serious 
bleeding complications with careful long-term monitoring and 
periprocedural management, and (3) to encourage ongoing 
adherence to these life-saving medications.[54]
This service should be driven by specialist physicians 
who are knowledgeable in the principles and practice of 
anticoagulation. Cardiologists and hematologists seem to 
be better trained to initiate and carry through this call. All 
the models of anticoagulation management service can 
be practiced successfully in Africa. The multiprofessional 
model, the clinical pharmacist model, the nurse model can 
be adapted to fit any hospital in Africa. The cardiologists 
and hematologists together with pharmacists and nurses 
who constitute multiprofessional unit are located in tertiary 
hospitals. The staff pharmacist and nurses and primary care 
physicians could be trained to do follow-ups in secondary 
and primary health care centers. This is possible with training 
that must ensure seamless education geared toward providing 
efficacious, safe and affordable anticoagulation.
The cardiologists and hematologists who are primary drivers 
must have access to the latest data and expert opinion via 
colleagues, academic literature, and internal and external 
meetings and congresses. They should be able to develop 
simple flowcharts outlining recommended indications, dose 
adjustment and follow-up. In addition they must provide 
education to other hospital departments and primary care 
doctors on treatment options for VTE/AF; provide education 
and training to anticoagulation clinic nurses (at least 6-monthly 
updates) regular updates). Very importantly they are also 
expected to guide the education of the patient about their 
condition and how it will be managed.[51,54]
The multiprofessional unit assess all patients needing 
anticoagulation and does basic laboratory tests.[23,53] 
Renal function tests (RFTs) are important because all 
NOACs are excreted to varying degrees by the kidneys 
with dabigatran being the highest. Renal impairment is 
determined according to creatinine clearance as calculated 
using the Cockroft and Gault formula and not the estimated 
glomerular filtration rate because it does not consider 
muscle mass. If CrCl is 30–60 ml/min, >75 years or fragile, 
then 6 monthly RFT is repeated. If CrCl is 15–30 ml/min, 
3 monthly RFT is done.
Liver function test is done as well and repeated if there are 
intercurrent conditions that may impact anticoagulation. 
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Deranged function will affect anticoagulation.[53] Hemoglobin 
level and blood group are also done as a baseline tests.[53]
Generic and specific coagulation assays (activated partial 
thromboplastin time or dilute thrombin time) for dabigatran, 
and prothrombin or anti-Factor Xa assays for direct Factor Xa 
inhibitors may be done and repeated in cases of emergency.[23,53] 
Table 4 outlines the actions to take in clinical conditions during 
use of NOACs.
Documentation of all current drugs the patient is on is 
important in order to address possible drug interaction.[23,53] 
All 4 NOACs interact with the P-gp transporter and all but 
dabigatran interact with CYP3A4.[54-58]
Strong inhibitors of P-gp and CYP3A4 include amiodarone (only 
for dabigatran), quinidine verapamin, azithromycin, 
clarithromycin, erythromycin, the fungal zoles (itraconazole, 
ketoconazole, posaconazole, voriconazole: only for dabigatran), 
HIV protease inhibitors (lopinavir, ritonavir, indinavir: not for 
dabigatran), immunosuppressants (Ciclosporin, Tacrolimus: 
only for dabigatran). These drugs should be avoided when 
NOAC is used or in cases of overriding co-administration or 
reduced renal function (CrCl 30–50 mL/min), reduce dose 
to half.
S t rong  induce r s  o f  P -gp  and  CYP3A4 inc lude 
Carbamazepine, Phenobarbital (not with dabigatran), 
Phenytoin, Primidone, Rifampicin, St John’s Wort (not 
with dabigatran). Avoid co-administration with NOAC or 
use with reduce dose in clinical conditions that indicate 
overriding use of NOAC.
Every patient on NOAC should have an anticoagulation card 
with full name and address of the patient, clear indication 
of the reason for anticoagulation, the type and dose of 
anticoagulant, time of intake, with or without food, when 
treatment was initiated, the name, phone number and address 
of the anticoagulation coordinator.
Patient should be well educated on the basic knowledge of 
their condition, treatment, desired period of anticoagulation, 
awareness of what to do if an adverse event occurs, and ability 
to differentiate between minor and major events. All possible 
drug–drug interactions should be explained to the patient and the 
patient should inform the health care giver whenever there is need 
to buy over the counter drugs. Patients should maintain regular 
contact with the supervising health care giver who is responsible for 
follow-up at a frequency dependent on individual risk assessment.
Patients on NOAC will need to understand that adherence is 
key to successful anticoagulation. Documentation of adherence 
is absolutely necessary. With shorter half-lives than warfarin, 
adherence to the NOACs is essential.
The frequency of monitoring will vary. Evaluation at the time 
of initiation of therapy is important, during surgery or any 
procedure will be required. Follow-up will be required within 
1 month, 3 months, 6 months following initiation of therapy; 
at the time of dose adjustment higher or lower.[59]
The challenge of coping with anticoagulation management 
in the era of NOAC in Africa
The very important challenge to the use of NOAC in Africa 
and other developing countries is the high out of pocket 
Table 4: Depicting the action to take in clinical conditions associated with management of non‑Vitamin K antagonist oral 
anticoagulants[59]
Clinical condition Action to take
When switching from warfarin to 
a NOAC
When switching from a NOAC to 
warfarin
The NOAC should be started when the INR is <2.5
Warfarin should be started and the NOAC continued until the INR is ≥2. Repeat the INR 1‑3 days after stopping 
NOAC to ensure INR remains therapeutic
For nonlife-threatening major 
bleeding event
Plasma levels of NOACs should normalize within 12-24 h for patients with normal renal function. It may take 
longer for patients with renal insufficiency, particularly for dabigatran
For life-threatening major bleeding 
event
Patients on dabigatran can be given idarucizumab 5 mg IV in two doses no more than 15 min apart
Patients taking factor Xa inhibitors should be given prothrombin complex concentrate 50 U/kg
All patients should receive supportive measures, including mechanical compression and endoscopic or surgical 
hemostasis (if applicable)
Following a major gastrointestinal 
bleeding event
NOACs should be restarted as early as feasible (usually 4-7 days) if the risk of stroke persists and outweighs the 
risk of recurrent bleeding
Surgery and procedures Most patients taking NOACs can safely undergo surgical procedures with a 24-48 h preprocedure hold
Longer hold times may be necessary for patients taking dabigatran who have chronic kidney disease. No bridging 
heparin is needed for NOAC-treated patients. Resume full-dose NOAC within 72 h postprocedure, once the 
bleeding risk is appropriate
Acute coronary syndrome needing 
intervention
For patients taking NOAC who present with an acute coronary syndrome, primary PCI can be performed 
(preferably using a radial approach) emergently for STEMI patients or delayed for 24-48 h in stable NSTEMI 
patients. Consider a proton pump inhibitor for patients taking combined NOAC with antiplatelet medications
Acute ischemic stroke For patients taking NOACs who present with an acute ischemic stroke, consider re-starting NOACs after 3-14 
days, depending on the degree of neurologic deficit and excluding any hemorrhagic transformation on brain 
computed tomography
PCI: Percutaneous coronary intervention, IV: Intravenous, STEMI: ST-segment elevation myocardial infarction, NSTEMI: Non-STEMI, NOACs: 
Non-Vitamin K antagonist oral anticoagulants, INR: International normalized ratio
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expenditure of patients. The health insurance system is very 
poorly developed in most African countries. In Nigeria for 
instance there is a health insurance scheme but the coverage is 
poor. It is also bedeviled with corruption and so does not lift the 
burden of expenditure from the ordinary citizen. This implies 
that inspite of the fact that the NOACs have better benefit‑risk 
and cost assessment ratio than warfarin, the average patient 
sees only the low unit cost of warfarin and so NOAC will 
continue to be less preferred.
The clinical indications for the use of NOAC will continue 
to expand as more clinical trials get on the way.[60] The use of 
NOACs in Africa will leap frog close to levels seen in USA 
and Europe if (1) The insurance scheme is overhauled and 
made to run efficiently so that patients can afford the high cost 
of NOACs. (2) The pharmaceutical companies bring down 
the cost of their products or if generic drugs are allowed to 
enter the market and make it more competitive. (3) There are 
anticoagulation policies that promote the establishment of 
anticoagulation management services. (4) Anticoagulation 
services are tailored to meet the peculiar health management 
system in Africa in such a way that the available staff are 
retrained to provide the much needed lifesaving service of 
anticoagulation.
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